Ulster University Logo

Siglec 1 and 2 as potential biomarkers in autoimmune disease

Eakin, Amanda, Bustard, Michael, McGeough, Cathy, Ahmed, Tahanver, Bjourson, AJ and Gibson, David (2016) Siglec 1 and 2 as potential biomarkers in autoimmune disease. Proteomics Clinical Applications, TBC . [Journal article]

Full text not available from this repository.

URL: http://onlinelibrary.wiley.com/doi/10.1002/prca.201500069/abstract;jsessionid=C7C043710A24F8C1BE08FC94F75CFDE8.f03t03

DOI: 10.1002/prca.201500069


Autoimmune diseases (AD) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarise these findings with particular focus on Siglec-1 and -2 involvement in AD. Fluctuations in these glycosylation dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.

Item Type:Journal article
Keywords:Glycosylation, Immune tolerance, Siglec
Faculties and Schools:Faculty of Life and Health Sciences > School of Biomedical Sciences
Faculty of Life and Health Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Stratified Medicine
ID Code:33004
Deposited By: Dr David Gibson
Deposited On:28 Jan 2016 12:08
Last Modified:19 Sep 2017 09:19

Repository Staff Only: item control page